As global markets continue to navigate a landscape of record highs and economic shifts, the potential for growth in smaller-cap stocks remains a focal point for investors. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.
Top 10 Penny Stocks Globally
| Name | Share Price | Market Cap | Rewards & Risks |
| EZZ Life Science Holdings (ASX:EZZ) | A$2.23 | A$114.63M | ✅ 4 ⚠️ 2 View Analysis > |
| Lever Style (SEHK:1346) | HK$1.36 | HK$864.4M | ✅ 4 ⚠️ 1 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD0.425 | SGD172.25M | ✅ 4 ⚠️ 2 View Analysis > |
| Van Elle Holdings (AIM:VANL) | £0.41 | £44.36M | ✅ 5 ⚠️ 2 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD2.21 | SGD8.7B | ✅ 5 ⚠️ 0 View Analysis > |
| Bredband2 i Skandinavien (OM:BRE2) | SEK2.47 | SEK2.36B | ✅ 4 ⚠️ 1 View Analysis > |
| DXN Holdings Bhd (KLSE:DXN) | MYR0.505 | MYR2.51B | ✅ 5 ⚠️ 0 View Analysis > |
| Zetrix AI Berhad (KLSE:ZETRIX) | MYR0.995 | MYR7.47B | ✅ 5 ⚠️ 2 View Analysis > |
| Croma Security Solutions Group (AIM:CSSG) | £0.835 | £11.5M | ✅ 4 ⚠️ 3 View Analysis > |
Click here to see the full list of 3,833 stocks from our Global Penny Stocks screener.
Let's take a closer look at a couple of our picks from the screened companies.
BRC Asia (SGX:BEC)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: BRC Asia Limited, with a market cap of SGD891.64 million, specializes in the prefabrication of steel reinforcement for concrete across Singapore and several international markets including Australia, Brunei, Hong Kong, Indonesia, Malaysia, Thailand, and India.
Operations: The company's revenue is derived from two primary segments: Trading, which contributes SGD255.23 million, and Fabrication and Manufacturing, accounting for SGD1.18 billion.
Market Cap: SGD891.64M
BRC Asia Limited, with a market cap of SGD891.64 million, has demonstrated strong financial health and growth potential. The company is trading at 63% below its estimated fair value, making it an attractive option for investors seeking undervalued opportunities. Its revenue streams from Trading and Fabrication and Manufacturing are robust, contributing significantly to its earnings growth of 10.3% over the past year—outpacing industry averages. BRC's debt management is commendable with a net debt to equity ratio of 19.6%, while short-term assets comfortably cover liabilities, ensuring financial stability amidst fluctuating market conditions.
- Navigate through the intricacies of BRC Asia with our comprehensive balance sheet health report here.
- Evaluate BRC Asia's prospects by accessing our earnings growth report.
Shenzhen Hemei GroupLTD (SZSE:002356)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Shenzhen Hemei Group Co., LTD. operates in the sale of clothing and accessories both in China and internationally, with a market cap of CN¥3.99 billion.
Operations: No specific revenue segments have been reported for Shenzhen Hemei Group Co., LTD.
Market Cap: CN¥4B
Shenzhen Hemei Group Co., LTD., with a market cap of CN¥3.99 billion, has shown significant revenue growth, reporting CN¥406.58 million for 2024 compared to CN¥164.99 million the previous year. Despite this growth, the company remains unprofitable with a net loss of CN¥43.69 million in 2024; however, losses have decreased over five years by 46.3% annually. The firm's short-term assets of CN¥575.5 million comfortably cover both short and long-term liabilities, indicating solid financial positioning despite ongoing challenges in achieving profitability and a negative return on equity at -7.94%.
- Get an in-depth perspective on Shenzhen Hemei GroupLTD's performance by reading our balance sheet health report here.
- Review our historical performance report to gain insights into Shenzhen Hemei GroupLTD's track record.
Jiangsu Huifeng Bio Agriculture (SZSE:002496)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Jiangsu Huifeng Bio Agriculture Co., Ltd. operates in the agricultural sector, focusing on the production and sale of agrochemical products, with a market cap of CN¥2.71 billion.
Operations: The company has not reported any specific revenue segments.
Market Cap: CN¥2.71B
Jiangsu Huifeng Bio Agriculture Co., Ltd., with a market cap of CN¥2.71 billion, has seen its debt to equity ratio improve significantly over five years, now at a satisfactory 20.5%. However, the company remains unprofitable with a negative return on equity of -14.64% and increasing losses over the past five years at 10.4% annually. While short-term assets do not cover short-term liabilities, long-term liabilities are adequately covered by these assets. Recent earnings reports show revenue growth but continued net losses, and auditors have expressed concerns about its ability to continue as a going concern.
- Unlock comprehensive insights into our analysis of Jiangsu Huifeng Bio Agriculture stock in this financial health report.
- Gain insights into Jiangsu Huifeng Bio Agriculture's past trends and performance with our report on the company's historical track record.
Where To Now?
- Access the full spectrum of 3,833 Global Penny Stocks by clicking on this link.
- Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if BRC Asia might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com